Tag: large hemispheric infarction
Post-hoc imaging analysis of CHARM trial identifies “promising” treatment signals in...
Brainomix and Remedy Pharmaceuticals have announced “promising new findings” from a post-hoc analysis of the Phase 3 CHARM trial. Presented at last week’s World...
Remedy announces upcoming presentation of “groundbreaking” CHARM study data at ISC...
Remedy Pharmaceuticals has announced that three speaker presentations reporting efficacy data from both the Phase 2 GAMES-RP and Phase 3 CHARM studies on its...
Remedy announces US FDA orphan drug designation to treat large-territory acute...
Remedy Pharmaceuticals has announced that the US Food and Drug Administration (FDA) Office of Orphan Products Division (OOPD) has granted orphan drug designation to...
Remedy announces Phase 3 CHARM trial data indicating Cirara’s potential in...
Remedy Pharmaceuticals recently announced promising new data from the Phase 3 CHARM clinical trial of Cirara (intravenous glyburide) in patients with large hemispheric infarction (LHI)—a...
